Eagle Pharmaceuticals (EGRX)
(Delayed Data from NSDQ)
$3.96 USD
-0.31 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.00 +0.04 (1.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.96 USD
-0.31 (-7.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.00 +0.04 (1.01%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Eagle Pharmaceuticals (EGRX) stock based on the movements in the options market lately.
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
by Indrajit Bandyopadhyay
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eagle Pharmaceuticals (EGRX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 12.38% and 8.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Surges 5.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 26th
by Zacks Equity Research
EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.
New Strong Sell Stocks for September 9th
by Zacks Equity Research
EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.
New Strong Sell Stocks for September 1st
by Zacks Equity Research
CCCS, BJRI and EGRX have been added to the Zacks Rank #5 (Strong Sell) List on September 1, 2022.
Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Eli Lilly's (LLY) Potential New Products Key to Growth
by Zacks Equity Research
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
Eagle Pharmaceuticals (EGRX) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -50.16% and 31.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B
by Zacks Equity Research
TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.